Lpath Inc.

Company Website

6335 Ferris Sq. Ste., A
San Diego, CA 92121

Sourcebook Data

View all the companies in Biomed & Biotech Firms - Publicly Traded*

Lpath Inc.

Market Cap as of 7/03/2014

$61,887,726

Market Cap as of 07/02/2013

$61,177,643

Market Cap as of 06/26/2012

$58,239,548

Market Cap as of 01/04/2012

$71,438,550

Market Cap as of 06/20/2011

$62,277,550

Market Cap as of 01/06/2011

$45,357,620

Exchange and Ticker Symbol

OTC BB: LPTN

Fields of Research

Focuses on the discovery and development of lipidomic-based therapeutic antibodies for treating human diseases primarily in the United States

Major Products

iSONEP (the ocular formulation of humanized Sphingomab)
ASONEP (the systemic formulation of humanized Sphingomab)
Lpathomab (a monoclonal antibody against lysophosphatidic acid)

Stocks

Company Trade Data

Stock Symbol Close Change Volume 52-Week
Chg %Chg High Low
LPTN
2.96
  0.05  
+ 1.72%
11,394,000
5.30
2.75

Executives

Scott Pancoast

  • Chief Executive Officer
  • President

Related News

Articles

Lpath outlines public offering

Lpath Inc. (Nasdaq: LPTN) will sell 2,366,000 shares of its common stock at a price to the public of $5 per share.

Lpath awarded NIH SBIR grant for Lpathomab

San Diego-based Lpath Inc. (Nasdaq: LPTN) was granted a $145,000 Phase 1 Small Business Innovative Research (SBIR) award from the National Institutes of Health.

Lpath announces new antibody program

Antibody developer Lpath Inc. has announced its new andibody program targeting respiratory disease.

Lpath withdraws from Pfizer process to assign iSONEP rights

San Diego's Lpath Inc. is no longer actively participating in Pfizer's process to assign the exclusive option it has for a worldwide license to develop and commercialize Lpath's iSONEP, a treatment for wet age-related macular degeneration.

Lpath receives US patent for ocular conditions

San Diego-based Lpath Inc. (Nasdaq: LPTN), a developer of bioactive lipid-targeted therapeutics, has received official notification from the U.S. Patent and Trademark Office that it has been issued another key patent supporting its iSONEP program.

Lpath reports interim results in cancer drug trial

Lpath Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has reported interim results in its Phase 2a trial investigating the drug Asonep as a treatment for metastatic renal cell carcinoma.

Similar Companies

Biological Product (except Diagnostic) Manufacturing325414
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES2836
Subscribe Today!